tetano
Editor, Senior Moderator
Am J Ophthalmol Case Rep
. 2022 Jun 11;101616.
doi: 10.1016/j.ajoc.2022.101616. Online ahead of print.
De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy
Chiaki Yamaguchi[SUP] 1 [/SUP], Hiroshi Kunikata[SUP] 1 2 [/SUP], Kazuki Hashimoto[SUP] 1 [/SUP], Masaaki Yoshida[SUP] 1 [/SUP], Takahiro Ninomiya[SUP] 1 [/SUP], Takehiro Hariya[SUP] 1 [/SUP], Toshiaki Abe[SUP] 3 [/SUP], Toru Nakazawa[SUP] 1 2 4 5 [/SUP]
Affiliations
Abstract
Purpose: Vogt-Koyanagi-Harada (VKH) disease after vaccination for coronavirus disease 2019 (COVID-19) is rare, and the prognosis for this condition and its effect on ocular blood flow remain unclear. The purpose of this paper is to present the first case of de novo VKH disease after the second vaccination for COVID-19 with an mRNA vaccine that was successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy (LSFG).
Observations: A 30s-year-old Japanese woman reported bilateral decreased visual function 2 weeks after receiving a second dose of the BNT162b2 mRNA vaccine. Best-corrected visual acuity was 20/50 OD and 20/70 OS. Optical coherence tomography revealed bilateral serous retinal detachment over the swollen choroidal layer. LFSG showed decreased blood flow in the peripapillary region of both eyes. This case was diagnosed as complete VKH syndrome, and the patient underwent systemic steroid therapy. After treatment, the retinal detachment disappeared and choroidal thickness decreased, and ocular blood flow increased. Three months later, visual acuity recovered to 20/20 in both eyes.
Conclusions: and Importance: Caution should be exercised in cases with visual symptoms after COVID-19 vaccination, even after more than one dose and more than one week after vaccination. LSFG may be a useful way to measure the ocular blood flow response to treatment and determine the prognosis for VKH disease after COVID-19 vaccination.
Keywords: COVID-19; Laser speckle flowgraphy; Mean blur rate; Vaccination; Vogt-Koyanagi-Harada disease; mRNA vaccine.
. 2022 Jun 11;101616.
doi: 10.1016/j.ajoc.2022.101616. Online ahead of print.
De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy
Chiaki Yamaguchi[SUP] 1 [/SUP], Hiroshi Kunikata[SUP] 1 2 [/SUP], Kazuki Hashimoto[SUP] 1 [/SUP], Masaaki Yoshida[SUP] 1 [/SUP], Takahiro Ninomiya[SUP] 1 [/SUP], Takehiro Hariya[SUP] 1 [/SUP], Toshiaki Abe[SUP] 3 [/SUP], Toru Nakazawa[SUP] 1 2 4 5 [/SUP]
Affiliations
- PMID: 35719316
- PMCID: PMC9187874
- DOI: 10.1016/j.ajoc.2022.101616
Abstract
Purpose: Vogt-Koyanagi-Harada (VKH) disease after vaccination for coronavirus disease 2019 (COVID-19) is rare, and the prognosis for this condition and its effect on ocular blood flow remain unclear. The purpose of this paper is to present the first case of de novo VKH disease after the second vaccination for COVID-19 with an mRNA vaccine that was successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy (LSFG).
Observations: A 30s-year-old Japanese woman reported bilateral decreased visual function 2 weeks after receiving a second dose of the BNT162b2 mRNA vaccine. Best-corrected visual acuity was 20/50 OD and 20/70 OS. Optical coherence tomography revealed bilateral serous retinal detachment over the swollen choroidal layer. LFSG showed decreased blood flow in the peripapillary region of both eyes. This case was diagnosed as complete VKH syndrome, and the patient underwent systemic steroid therapy. After treatment, the retinal detachment disappeared and choroidal thickness decreased, and ocular blood flow increased. Three months later, visual acuity recovered to 20/20 in both eyes.
Conclusions: and Importance: Caution should be exercised in cases with visual symptoms after COVID-19 vaccination, even after more than one dose and more than one week after vaccination. LSFG may be a useful way to measure the ocular blood flow response to treatment and determine the prognosis for VKH disease after COVID-19 vaccination.
Keywords: COVID-19; Laser speckle flowgraphy; Mean blur rate; Vaccination; Vogt-Koyanagi-Harada disease; mRNA vaccine.